PubMed Journals Articles About "Aquagenic Pruritus In Myeloproliferative Neoplasms" RSS

04:51 EDT 24th August 2019 | BioPortfolio

Aquagenic Pruritus In Myeloproliferative Neoplasms PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Aquagenic Pruritus In Myeloproliferative Neoplasms articles that have been published worldwide.

More Information about "Aquagenic Pruritus In Myeloproliferative Neoplasms" on BioPortfolio

We have published hundreds of Aquagenic Pruritus In Myeloproliferative Neoplasms news stories on BioPortfolio along with dozens of Aquagenic Pruritus In Myeloproliferative Neoplasms Clinical Trials and PubMed Articles about Aquagenic Pruritus In Myeloproliferative Neoplasms for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aquagenic Pruritus In Myeloproliferative Neoplasms Companies in our database. You can also find out about relevant Aquagenic Pruritus In Myeloproliferative Neoplasms Drugs and Medications on this site too.

Showing "Aquagenic Pruritus Myeloproliferative Neoplasms" PubMed Articles 1–25 of 578

Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.

Thromboses and phenotypic evolutions (leukemia, myelofibrosis) are the most frequent complications in Polycythemia vera (PV) and essential thrombocythemia (ET). Aquagenic pruritus (AP) is not only PV symptom, but is also present in ET. The presence of pruritus in PV is associated with a lower risk of arterial thrombosis. Among 396 ET patients, presence of AP characterizes patients with higher risk of morbidity: more proliferative, more symptomatic at diagnosis and higher risk of thromboses and evolutions. T...

Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms.

To analyze the incidence, hemogram, genetics, clinical manifestations, therapeutic efficacy and outcome of patients with myeloproliferative neoplasms(MPN) so as to provide much more therapeutic basis for clinically studying the pathogenesis, diagnosis, and treatment as well as evaluating the prognosis of MPN patients.

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.

Canonical Janus kinase 2 (JAK2) V617F and exon 12 mutations in myeloid neoplasms are well described. There are limited reports of other JAK2 variants of potential clinical relevance. This study was designed to survey JAK2 variants in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML) and to determine their contributions to disease pathogenesis.

Age at diagnosis is an important prognostic factor in Philadelphia-negative Myeloproliferative Neoplasms.

Merav Barzilai and others recently conducted a retrospective study on 109 patients with Philadelphia-negative Myeloproliferative Neoplasms (MPNs) aged between 18 and 45 years (1). The authors conclude that the risk of death and progression to myelofibrosis and leukemia in this population is similar to that found in the counterpart over the age of 45 years. Our experience does not confirm Barzilai's data. This article is protected by copyright. All rights reserved.

Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response.

Myeloproliferative Neoplasms: A Primer for Radiologists.

The myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Knowledge of the radiological and clinical features of MPNs and their associated complications is critical for interpreting radiologists. The purpose of this article is to provide a primer to radiologists summarizing the modern understanding of MPNs from an imaging-based perspective, including common disease-related findings and complications relate...

The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

The classic, chronic Philadelphia chromosome negative myeloproliferative neoplasms (MPN)-essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF)-are clonal malignancies of hematopoietic stem cells and are associated with myeloproliferation, organomegaly, and constitutional symptoms. Expanding knowledge that chronic inflammation and a dysregulated immune system are central to the pathogenesis and progression of MPNs serves as a driving force for the development of agents affecting the ...

Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples.

Cytogenetics is essential in myeloid neoplasms (MN) and pre-analytical variables are important for karyotyping. We assessed the relationship between pre-analytical variables (time from collection to sample processing, material type, sample cellularity, and diagnosis) and failures of karyotyping. Bone marrow (BM, n=352) and peripheral blood (PB, n=69) samples were analyzed from acute myeloid leukemia (n=113), myelodysplastic syndromes (n=73), myelodysplastic syndromes/myeloproliferative neoplasms (n=17), mye...

Lessons Learned in the Development of a Computable Phenotype for Response in Myeloproliferative Neoplasms.

Determining response status in patients with myeloproliferative neoplasms is a complex problem requiring the integration of both structured and unstructured data elements from disparate information systems. By applying multiple techniques, a collaborative team of informatics professionals and research personnel were able to determine which elements were amenable to automated extraction and which required expert adjudication. With this knowledge in mind, we were able to build a system that joins together pro...

Methyl Paraben May Increase the Risk of Pruritus in African Americans Whereas Triclosan Is Inversely Associated With Pruritus and Eczema.

Phenols and parabens (P&Ps) are commonly found in skin care products. However, P&Ps' role in pruritus and eczema has not been studied.

Vorinostat synergizes with Antioxidant therapy to target Myeloproliferative Neoplasms.

The BCR-ABL-negative myeloproliferative neoplasms (MPN) are driven by JAK-STAT pathway activation but epigenetic alterations also play an important pathophysiological role. These can be pharmacologically manipulated with histone deacetylase inhibitors (HDACis), which have proven to be clinically effective in the treatment of MPN but exhibiting dose-limiting toxicities. The treatment of primary MPN cells with Vorinostat modulates the expression of genes associated with apoptosis, cell cycle, inflammation and...

Treatments for chronic pruritus outside of the box.

Patients with chronic pruritus are in desperate need of novel treatment options, as current therapeutic possibilities are often not effective, have a poor level of evidence and are mostly off label. In recent years, much effort has been put into the identification of potential targets for the treatment of chronic pruritus. More importantly, a number of promising new drugs that are aimed at treating pruritus in different conditions are currently in advanced stages of clinical trials. Here, current pharmacolo...

Defining the Role of Mirtazapine in the Treatment of Refractory Pruritus.

Mirtazapine has traditionally been used for the treatment of major depressive disorder, with an added benefit in patients who have comorbid insomnia or anxiety. Recent studies describe its usefulness in treating refractory pruritus of various causes as well. Our goal is to better define the use of mirtazapine in the treatment of refractory pruritus. Through a thorough literature review, we identified all reports of the use of mirtazapine for pruritus. We found that mirtazapine has quality evidence for the t...

Insulin Resistance and Hepatitis C Virus-Associated Subclinical Inflammation Are Hidden Causes of Pruritus in Egyptian Hemodialysis Patients: A Multicenter Prospective Observational Study.

Pruritus is one of the most common and disturbing symptoms in hemodialysis (HD) patients. The pathogenesis of pruritus in HD patients is multifactorial; however, a little progress in understanding this pathogenesis has been achieved.

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis.

Atopic dermatitis (AD) is an inflammatory skin disease with a chronic, relapsing course. Clinical features of AD vary by age, duration, and severity but can include papules, vesicles, erythema, exudate, xerosis, scaling, and lichenification. However, the most defining and universal symptom of AD is pruritus. Pruritus or itch, defined as an unpleasant urge to scratch, is problematic for many reasons, particularly its negative impact on quality of life. Despite the profoundly negative impact of pruritus on pa...

Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare disease in the 2016 revised World Health Organization (WHO) classification. Diagnostic criteria include the following: persistent thrombocytosis (>450 × 10 /L) with clustering of atypical megakaryocytes, refractory anemia, dyserythropoiesis with ring sideroblasts, and the presence of the spliceosome factor 3b subunit (SF3B1) mutation. It is unclear if anemia should be a required criterion for th...

Influence of Climate on Google Internet Searches for Pruritus Across 16 German Cities: Retrospective Analysis.

The burden of pruritus is high, especially among patients with dermatologic diseases. Identifying trends in pruritus burden and people's medical needs is challenging, since not all affected people consult a physician.

Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population.

Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of refractory rash and pruritus in Chinese malignancy population. patients showed a rapid recovery from refractory pruritus, no adverse events occurred. Weekly follow-up visits showed the pruritus were stable and no ...

Peripheral sensitisation and loss of descending inhibition is a hallmark of chronic pruritus.

Neurophysiological mechanisms leading to chronicity of pruritus are not yet fully understood and it is not known whether these mechanisms diverge between different underlying diseases of chronic pruritus. This study aimed to detect such mechanisms in chronic pruritus of various origins. One-hundred and twenty patients with chronic pruritus of inflammatory origin (atopic dermatitis), neuropathic origin (brachioradial pruritus) and chronic prurigo of nodular type, the latter as a model for chronic scratching,...

Strong Associations Between Inflammation, Pruritus and Mental Health in Dialysis Patients.

Pruritus, impaired mental health and inflammation contribute to morbidity in end-stage renal disease. There are no studies on all three conditions. We therefore obtained inflammatory parameter data (C-reactive protein and interleukin-6), pruritus data and psychological test data (36-Item Short-Form Health Survey, "Allgemeine Depressionsskala" and Toronto Alexithymia Scale-20) for 19 dialysis patients with pruritus, 20 dialysis patients without pruritus and 15 healthy controls. Non-parametric hierarchical cl...

How to define chronic pruritus - symptom or disease?

Chronic pruritus is defined by itching lasting 6 weeks or more and is known to be both a highly prevalent and burdensome symptom of many pruritogenic diseases. Its status as a symptom has many implications mainly that the symptom should evolve and subside with the disease. However, according to the clinical experience, chronic pruritus often does not parallel the disease course and requires an own management. It is speculated, that neuronal sensitization processes take place which lead to disconnection of t...

Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Lymphoblastic leukemia (ALL) following myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) is very rare. We report five cases: four had ALL diagnosed after MDS or MDS/MPN and one had ALL and MDS diagnosed simultaneously. At the onset of ALL, all patients showed co-existing MDS or MDS/MPN. Map-back FISH was performed in four patients, showing that ALL and MDS were cytogenetically related in two patients and unrelated in the other two patients. All five patients were treate...

Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.

Marrow fibrosis is a significant complication of myeloproliferative neoplasms (MPN) that affects up to 20% of patients and is associated with a poor prognosis. The pathological processes that lead to fibrotic progression are not well understood, but megakaryocytes have been implicated in the process. The aim of this study was to determine whether platelets, derived from megakaryocytes, have transcriptomic alterations associated with fibrosis. Platelets from MPN patients with and without fibrosis and non-mal...

Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin.

Pruritus is a major symptom of many inflammatory diseases and impacts greatly the quality of life in patients. We aimed to specify the characteristics of experimentally induced pruritus in normal skin and in experimentally induced inflammatory dermatitis in healthy volunteers.

Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms.

The 60 American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13 Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on the 4 -5 December 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open quest...

Quick Search